26 Prospective evaluation of clinical benefit and cost of plasma-first next-generation sequencing for the genomic assessment of patients with newly diagnosed advanced non-small cell lung cancer
O Brien Cathal , Counihan Ian , Ryan Cliona , Barrett Helen , O'Shea Ann Marie , Cuffe Sinead , Korpanty Grzegorz , Prior Lisa , Barr Martin P , Finn Stephen , Teo Minh Yuen , McCarron Sarah , Cummins Rob , Toomey Sinead , Hennessy Bryan , Sorensen Jan , Bennett Kathleen , Nadarajan Parthiban , Doyle Brendan , Naidoo Jarushka , O Reilly David
{"title":"26 Prospective evaluation of clinical benefit and cost of plasma-first next-generation sequencing for the genomic assessment of patients with newly diagnosed advanced non-small cell lung cancer","authors":"O Brien Cathal , Counihan Ian , Ryan Cliona , Barrett Helen , O'Shea Ann Marie , Cuffe Sinead , Korpanty Grzegorz , Prior Lisa , Barr Martin P , Finn Stephen , Teo Minh Yuen , McCarron Sarah , Cummins Rob , Toomey Sinead , Hennessy Bryan , Sorensen Jan , Bennett Kathleen , Nadarajan Parthiban , Doyle Brendan , Naidoo Jarushka , O Reilly David","doi":"10.1016/j.lungcan.2025.108137","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108137"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500225001102","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
期刊介绍:
Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.